arrow
S

Sandra P. Susanibar-Adaniya

University of Pennsylvania
H指数:10
被引数:1,035

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy

CD4 T细胞介导BCMA car-t细胞治疗后car-t细胞相关的免疫相关不良事件

2026-01-150
PRE
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience

外周髓外和骨旁浆细胞瘤对使用teclistamab治疗的多发性骨髓瘤患者治疗结局的影响:美国骨髓瘤免疫治疗联盟真实世界经验

2025-11-280
OAAI
Outcomes of relapse after teclistamab therapy in multiple myeloma

接受特昔利珠单抗治疗后多发性骨髓瘤复发的结局

2025-11-050
OAAI
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

接受过BCMA靶向疗法的复发/难治性多发性骨髓瘤患者中teclistamab的治疗效果:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-06-250
OAAI
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the US Multiple Myeloma Immunotherapy Consortium

复发难治性多发性骨髓瘤(RRMM)老年患者接受teclistamab治疗后的结局:一项来自美国多发性骨髓瘤免疫治疗联盟的多中心研究

2025-05-090
OA
Efficacy and Safety of Anti-CDI9 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

抗CDI9和抗BCMA嵌合抗原受体(CAR)T细胞疗法在自身免疫性疾病、淋巴瘤或骨髓瘤患者中的疗效与安全性

BLOOD
IF23.1
2024-11-050
PRE
Tasquinimod, an S100A9 Inhibitor, in Combination with Ixazomib, Lenalidomide, and Dexamethasone for Relapsed and Refractory Multiple Myeloma

Tasquinimod,一种S100A9抑制剂,与伊沙佐米、来那度胺和地塞米松联合用于复发性和难治性多发性骨髓瘤。

BLOOD
IF23.1
2024-11-050
PRE
EZHI/2 Inhibition Improves the Anti-Tumor Efficacy of CAR and TCR T-Cell Based Therapies Against Multiple Liquid and Solid Tumors

EZHI/2抑制提高了CAR和TCR T细胞为基础疗法对多种液体和实体肿瘤的抗肿瘤疗效

BLOOD
IF23.1
2024-11-050
PRE
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

商业CAR T细胞治疗后T细胞淋巴瘤和继发性原发性恶性肿瘤风险

2024-01-2481
PRE
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy

抗BCMA/CD19 CAR T细胞与多发性骨髓瘤的早期免疫调节维持对初始或后续治疗有反应

2022-11-2144
OAAI
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
2017-06-0136
OAAI
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
2017-05-1825
OAAI